Lung Diseases, Sleep, Smoking
Conditions
Brief summary
This 5-year prospective, observational study will: (1) determine the individual, social, and environmental predictors of sleep duration, quality, latency, efficiency, timing and regularity in African American smokers, (2) quantify the prospective relationship between multiple metrics of sleep with tobacco use, such that a sleep phenotype of risk for smoking is defined, and (3) examine the extent to which short sleep (\<7 hrs) and other unhealthy sleep metrics, predicts lung function through smoking behaviors and inflammation, in 480 African Americans at risk for advancing COPD (GOLD Stage 0-2 and current smoker). Study subjects will be recruited via Temple Health System sites. Following eligibility screening, initially eligible subjects will provide written study consent and complete an in-home sleep assessment to rule out the exclusionary moderate-severe sleep apnea and other sleep disorders. Consenting and eligible subjects will be entered into the study and across the 60-month data collection period, complete 8 assessments: 4 annual clinical based assessments, interspersed by 4 mid-year, phone-based, self-report assessments.
Interventions
OTHERCohort Observational study
Cohort Observational study - there is no intervention
Sponsors
National Institutes of Health (NIH)
National Institute on Minority Health and Health Disparities (NIMHD)
Temple University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 67 Years
Healthy volunteers
Yes
Inclusion criteria
1. Self-reported African American, White, or mixed ethnicity. 2. 40 - 67 years. 3. GOLD stage 0-3 as assessed by spirometry. 4. No moderate-severe sleep disorders or use of sleep medication. 5. Self-reported current cigarette smoker as defined by smoking one or more cigarettes in the last month. 6. Able to communicate in English and provide written informed consent.
Exclusion criteria
1. Self-reported ethnicity (in full or part) other than Black/African American or White. 2. \< 40 years of age. 3. Not a current cigarette smoker (\< 1 cigarette in last month). 4. GOLD stage \>3. 5. Presents with a diagnosed moderate-severe sleep disorder 6. Use of any sleep medication. -
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| FEV1/FVC ratio | 365 days | Lung function as defined as the ratio of Forced Expiration Volume in one second (FEV1) to the Forced Vital Capacity (FVC; FEV1/FVC ratio) will be computed |
Countries
United States
Outcome results
None listed